Integration of Biomarkers & Imaging to Define Patient Response in a Phase I/II Clinical Trial

• Outlining a strategy for integrating diverse data streams, from molecular biomarkers to advanced imaging, to create a unified view of patient response
• Discussing how real-time insights from biomarkers and imaging can inform dynamic adjustments to drug dosage and treatment schedules, moving beyond traditional safety metrics
• Exploring how this integrated approach can provide a more robust and evidence based foundation for making critical decisions about advancing the drug to a larger trial

Speakers:

Francesca Barone

Chief Scientific Officer

Candel Therapeutics